Darrers avenços en el desenvolupament de fàrmacs biotecnològics multi-domini

Abstract

Given the growing interest in multi-domain biotechnological drugs due to their potential to

improve the pharmacokinetic and pharmacodynamic properties of conventional protein drugs,

this literature review aims to provide a detailed or comprehensive description of the most

recent advances in the development of these drugs.

First, it describes what fusion proteins, multi-domain drugs, pharmacokinetics and

pharmacodynamics are, mentioning the properties that these drugs can improve. Next, it

describes the functional domains that can form part of these molecules, such as domains that

allow them to cross physiological barriers, protein transduction domains, and receptor-binding

domains, among others, explaining the function of each and the mechanisms by which they

exert their therapeutic action.

This paper also reviews the most relevant studies in this field, as well as the current and

potential therapeutic applications of these drugs in pathologies such as cancer and

neurodegenerative disorders such as Alzheimer. Finally, the main limitations facing these types

of therapies are analysed, including structural stability, immunogenicity and complexity in their

production.

This analysis allows us to assess the emerging role of multi-domain drugs in biomedical

innovation and their future prospects in the design of more effective and personalised

therapies

3